<DOC>
	<DOCNO>NCT00883415</DOCNO>
	<brief_summary>This study examine patient chronic kidney disease-related anemia measure change metabolism heart use FDG/PET scanning , 6 month health-care provider initiate anemia management therapy FDA-approved drug darbepoetin alfa ( Aranesp ) , approve chronic kidney disease-related anemia . The investigator hypothesize heart abnormal metabolism anemia chronic kidney disease improve correction anemia darbepoetin alfa .</brief_summary>
	<brief_title>Myocardial Glucose Uptake ( MGU ) Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Participant must receive care VAMHCS ( VA Hospital ) Baltimore Diagnosed CKD stage 3 5 ( eGFR 60 ml/min/1.73m2 ) expect initiate renal replacement therapy within 6 month Anemia relate CKD . The last 2 serum hemoglobin ( Hb ) value less 11.0 gm/dl great 8.0 gm/dl Greater 18 year age Assessed clinically stable clinician Need hemodialysis , peritoneal dialysis , transplantation time enrollment project start within 6 month enrollment Low functional capacity include inability walk flight stair bag grocery ( NYHA Class III/IV Heart Failure ) Prior erythropoietic agent within last 12 week TSAT &lt; 15 % receiving recommend dose iron deficiency Uncontrolled hypertension define great 180 mm Hg systolic 110 mm Hg diastolic Potentially `` brittle '' diabetes propensity symptomatic hypoglycemia 6 hour fast New diagnosis ongoing therapy Cancer Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>metabolism</keyword>
	<keyword>myocardium</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>